Alerta

CD59 FOR INHIBITING INFLAMMASOME ACTIVATION

Absstract of: US20260232845A1

Methods and kits are provided for inhibiting inflammasome activation in cells of a subject or an inflammation-affected eye in a subject by administering to the subject a composition including a nucleotide sequence encoding a membrane independent CD59 protein operably linked to a promoter for expression and secretion of the membrane independent CD59 protein in the cells or the inflammation-affected eye, the composition inhibiting inflammasome activation.

U-p53 PEPTIDES AS MARKERS IN THE RATE OF PROGRESSION OF COGNITIVE DECLINE TO ALZHEIMER'S DISEASE

Absstract of: US20260235628A1

0000 U-p53 peptide P1 is useful in the determination of the rate of progression of Alzheimer's disease (AD). By quantitating the level of U-p53 peptides in a subject's biological sample, the rate of progression of Alzheimer's disease at the pre-clinical and prodromal stages of the disease in a subject can be determined.

LTBP COMPLEX-SPECIFIC INHIBITORS OF TGF-BETA 1 AND USES THEREOF

Absstract of: US20260234272A1

Disclosed herein are inhibitors, such as antibodies, and antigen binding portions thereof, that selectively bind complexes of LTBP1-TGFβ1 and/or LTBP3-TGFβ1. The application also provides methods of use of these inhibitors for, for example, inhibiting TGFβ1 activation, and treating subjects suffering from TGFβ1-related disorders, such as fibrotic conditions. Methods of selecting a context-dependent or context-independent isoform-specific TGFβ1 inhibitor for a subject in need thereof are also provided.

Polyphenol-Containing Compositions for Upregulating Camp Gene Expression

Absstract of: US20260232624A1

0000 A method is for modulating tight junction (TJ) integrity in a subject. The method includes (a) assessing TJ integrity in the subject by quantifying at least one biomarker of TJ integrity in the subject; (b) administering to the subject a first composition containing (i) at least one polyphenol, and (ii) a second substance which is not a polyphenol and which upregulates CAMP gene expression in the subject; (c) reassessing TJ integrity in the subject by quantifying at least one biomarker of TJ integrity in the subject; and (d) repeating steps (b) and (c) until the value of said at least one biomarker is within a target range.

METHOD OF IMAGING BIOMOLECULES

Absstract of: US20260235515A1

Identification of molecular species in a sample based unique fluorescent labeling, light dispersion, and image processing. The molecular species identification methods can be used for diagnosing diseases.

ENDOTHELIAL AND BLOOD-BRAIN BARRIER MARKERS OF NEUROLOGICAL DISORDERS

Absstract of: US20260235629A1

0000 Disclosed are methods, compositions, and computer-implemented systems for diagnosing, staging, and monitoring neurological and neurovascular disorders, including Alzheimer's disease, vascular dementia, traumatic brain and spinal-cord injury, stroke, demyelinating disease, and central nervous system vasculitis. The invention involves measuring levels of endothelial and blood-brain-barrier-associated biomarkers—comprising claudins 1-34 (including claudin-14 and claudin-23), endothelins (ET-1 to ET-3), ESAM, ESM1 (Endocan), neuropilins (NRP1 and NRP2), ZIC1, FOXP2, and neuroligins (NLGN 1-4 and subtypes)—in biological samples such as cerebrospinal fluid, plasma, serum, or other biofluids. Altered biomarker patterns indicate endothelial activation, barrier dysfunction, or neurovascular signaling imbalance associated with disease progression or therapeutic response. Also provided are analytical kits containing capture reagents, calibration standards, and a non-transitory computer-readable medium configured to integrate biomarker data, as well as machine-learning models trained to generate diagnostic, prognostic, or vascular-safety indices supporting individualized management of neurodegenerative and neurovascular conditions.

HUMAN NEURONAL CIRCUITS

Absstract of: WO2026166999A1

The present invention relates to a human cortico-striato-nigral circuit on chip comprising: i) a population of human striatal medium spiny neurons (MSNs) MSNs expressing MEIS2, BCL11B and GABAergic lineage markers GAD2 and DLX6-AS1, said MSNs thereby forming a medium spiny neuronal circuit, wherein said medium spiny neuronal circuit comprises at least two subpopulations of MSNs expressing dopaminergic D1- or D2- receptors; ii) a population of nigral dopaminergic neurons expressing FOXA1, LMX1A, EN1 and NR4A2, thereby forming a nigral dopaminergic neuronal circuit; and iii) a population of cortical glutamatergic neurons expressing LHX2 and SLC17A6 and/or SLC17A7, thereby forming cortical circuit; a multi-electrode array (MEA) chip for recording neuronal activity, said neuronal activity resulting at least in part from dopaminergic, GABAergic and/or glutamatergic neurotransmission; wherein said medium spiny neuronal circuit is spatially arranged onto said MEA chip for receiving excitatory and/or modulatory inputs from said cortical circuit iii) and/or said nigral dopaminergic circuit ii); and wherein each one of said populations i)-iii) are differentiated from a human pluripotent stem cell. The present invention further relates to a method for producing said cortico-striato-nigral circuit on chip, and a method of determining the effect of a candidate agent on neuronal activity of the cortico-striato- nigral circuits on chip.

T CELL RECEPTORS AND MODIFIED T CELLS FOR NEURODEGENERATIVE AND OTHER INFLAMMATORY DISORDERS

Absstract of: WO2026170050A1

In one aspect, the present invention provides nucleic acids encoding T cell receptor alpha and beta chains which can associate with each other in order to form functional T cell receptors (TCRs) specific for cryptic epitopes of, for example, HDGFL2 protein, IgLON5 protein and others expressed by a target cell. In other aspects, the invention provides T cell receptors (TCRs) specific for cryptic epitopes, modified T cells expressing the T cell receptors, methods for generating the modified T cells, and diagnostic/screening methods for identifying subjects expressing TCRs comprising antigen specificities for cryptic peptides associated with TDP-43 proteinopathies. In further aspects, the invention provides a method for stimulating an immune response, treating a subject with a TDP-43 proteinopathy, such as amyotrophic lateral sclerosis (ALS) or inclusion body myositis (IBM), and detecting a TDP-43 proteinopathy-associated immune signature in a subject.

PATHOLOGIC TDP-43 AS A BIOMARKER FOR THE DIAGNOSIS OF TDP-43 PROTEINOPATHY

Absstract of: US20260234229A1

Disclosed herein are antibodies or antigen-binding fragments thereof and compositions comprising the same. Also disclosed are methods of detecting TAR DNA-binding protein 43 (TDP-43) in a biological sample, diagnosing a neurodegenerative disease in a subject, and selecting whether to enroll a subject in a clinical trial for frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) using the antibodies or antigen-binding fragments thereof described herein. In addition, disclosed herein are immunoassay kits for selectively detecting TDP-43 in a biological sample.

METHODS FOR DETERMINING ABNORMAL CSF FLOW

Absstract of: WO2026167161A1

The present invention relates to biomarkers of cerebrospinal fluid (CSF) flow, methods for determining the synthesis rate and clearance rate of biomolecules in CSF of a subject, methods for determining abnormal CSF flow in a subject and diagnosing and treating disorders associated with abnormal CSF flow.

GDF11 BIOMARKERS, METHODS, AND COMPOSITIONS FOR TREATING STROKE

Absstract of: WO2026169642A2

The disclosure relates to methods of treating stroke, dosing regimens of GDF11, and post-stroke treatment with GDF11.

METHOD OF DIAGNOSING A SUBPOPULATION OF SUBJECTS WITH A POST-COVID-19 CONDITION AND OF TREATING THE SUBJECTS USING BAFF INHIBITION

Absstract of: WO2026165666A1

The present disclosure provides a method for treating long CO VID ( e.g., severe long CO VID) or at least one symptom thereof in a subpopulation of subjects displaying a combination of biomarkers namely a blood level of secreted B-cell activating factor and of membrane BAFF in white blood cells higher than a corresponding reference level; and at least one of blood level of precursor- like marginal zone B-cell populations, zonulin, anti-Mi-2 nuclear antigen autoantibodies, anti-SmD autoantibodies, anti-Ul-snRNP-A autoantibodies, anti-RCN2 autoantibodies, lipopolysaccharide-binding protein (LBP), and p-D-glucan higher than a corresponding reference level, and APRIL lower than a corresponding reference level, comprising administering a therapeutically effective amount of a BAFF inhibitor to the subject. It also provides a method of diagnosing a subject as having long CO VID using the combination of biomarkers and a diagnosis kit comprising ligands for the biomarkers.

METHODS AND COMPOSITIONS FOR TREATING HEART FAILURE WITH REDUCED EJECTION FRACTION

Absstract of: WO2026169645A1

Embodiments provided herein relate to methods, compositions and uses for treating heart failure with reduced ejection fraction (HFrEF). Some embodiments relate to methods, compositions and uses of a recombinant viral vector encoding a 2a isoform of a sarco(endo)plasmic reticulum calcium ion (Ca2+) ATPase (SERCA2a) protein.

生体膜小胞の網羅的解析方法

Absstract of: JP2026130617A

0001 【課題】 本発明は、生体膜小胞についての従来の解析方法では十分に解析できなかった生体膜小胞の機能を詳細に解析することを目的に、生体膜小胞を網羅的に解析することを課題とする。 【解決手段】 本発明は、生体膜小胞についての解析を行う際、分離または精製を行っていない生体膜小胞を解析対象とすることにより、従来法においては解析データを取得できていなかった生体膜小胞を含めすべての生体膜小胞についてのデータを取得し、そのデータを利用して生体膜小胞の網羅的解析を可能にすることを明らかにし、前記課題を解決した。 【選択図】 なし

ANTI-VISTA ANTIBODIES AND FRAGMENTS

Absstract of: US20260234264A1

The present invention relates to novel antibodies and fragments that bind to a V-domain Ig Suppressor of T cell Activation (VISTA), and methods of making and using same. Methods of use include methods of treatment of cancer, including leukemias, lymphomas, solid tumors and melanomas.

BIOMOLECULES IN DISEASE

Absstract of: US20260235627A1

The invention relates to methods of screening for the presence of proteopathies, to methods of diagnosing proteopathies, to methods of differentially diagnosing proteopathies, to methods of assessing the severity, stage and/or prognosis of proteopathies, and to methods for monitoring the progression of proteopathies. The invention also relates to methods for determining the efficacy of therapeutic interventions for proteopathies.

BIOMARKERS FOR HUNTINGTON DISEASE STRATIFICATION, METHODS AND USES THEREOF

Absstract of: US20260235626A1

The present invention relates to biomarker-based analyses for the stratification of Huntington Disease (HD) in a subject. The invention further relates to protein biomarkers (and particular combinations) and their use in monitoring biochemical changes in HD patients indicative of the stage, severity, progression, or age-of-onset of disease; guidance for the design of clinical trials; for selecting a therapeutic regimen and monitoring response to treatment. The invention further comprises methods for the detection of HD biomarkers in cerebrospinal fluid (CSF) and other biofluids in patients with HD or at risk of developing HD.

PROTEINS AND PROTEIN LIBRARIES

Absstract of: US20260234206A1

0000 The present invention relates to proteins and protein libraries particularly for use in methods of screening to identify novel binding partners including diagnostic and therapeutic molecules.

ペンタアザ大環状環複合体およびホルモン療法剤の併用がん治療法

Absstract of: WO2021247009A1

A method of treating a cancer in a mammalian subject with a tumor signature characterized by any one or more of (i) a level of sirtuin (SIRT3) protein that is below a first predetermined threshold level, (ii) a level of manganese superoxide dismutase acetylated at the lysine 68 residue (AcK68) that exceeds a second predetermined threshold level, and (iii) expression levels of hypoxia-inducible factor 2α (HIF2α) that exceed a third predetermined threshold level indicative of lineage plasticity for stemness, the method comprising administering to the mammalian subject a therapeutically effective amount of a pentaaza macrocyclic ring complex corresponding to the Formula (I) below, optionally with administration of a further anti-cancer therapeutic agent.

灌流低下を特徴とする状態の検出および治療

Absstract of: WO2021236836A2

Methods of detecting a condition comprising neoangiogenesis, ischemia, or both, or risk thereof in a subject. Methods of inhibiting, ameliorating, delaying the onset of, reducing the likelihood of, treating, or preventing a condition comprising perfusion shortage (such as neoangiogenesis, ischemia, or both) in a subject in need thereof are described. Kits are described.

ＣＤ３３を標的にするキメラ抗原受容体

Absstract of: WO2021202793A2

Chimeric antigen receptors (CARs) with binding domains derived from a novel suite of CD33-binding antibodies are described. The CARs include optimized short and intermediate spacer regions. The current disclosure also provides methods of cell expansion/activation processes utilizing IL-2, IL-7, IL-15, and/or IL-21 that improve cellular proliferation and cell lysis of the CARs as described.

筋萎縮性側索硬化症（ＡＬＳ）と関連するバイオマーカー

Absstract of: WO2025058005A1

Provided is a biomarker for use in the determination or diagnosis of a progression rate of amyotrophic lateral sclerosis (ALS) or a possibility of being affected by ALS and/or the selection or prediction of a therapeutic drug for ALS.　There is discovered a biomarker selected from the group consisting of IL-17A, KLRD1, KRT19, NCF2, TFF2, YTHDF3, Th17, a regulatory T cell (Treg), mature CD8T, naive CD8T, exhausted CD8T, a Classical monocyte, memory CD4T, Th17/Treg, mature CD8T/naive CD8T, and mature CD8T/exhausted CD8T.

프로스타글란딘 F2 수용체 억제제에 대한 항체 및 접합체 및 그의 용도

Absstract of: WO2024215624A2

This disclosure provides antibodies and methods for preparing and using the same wherein the antibodies bind to PTGFRN on a cell.

DIAGNOSIS, PROGNOSIS, MONITORING AND/OR TREATMENT OF COMORBIDITIES IN PEOPLE LIVING WITH HUMAN IMMUNODEFICIENCY VIRUS

Absstract of: EP4790418A1

0001 The present invention refers to the diagnosis, prognosis, monitoring and/or treatment of comorbidities in people living with human immunodeficiency virus (HIV) (PLWH).

ＰＭＬの危険性を査定する方法

Nº publicación: JP2026129934A 12/08/2026

Applicant:

バイオジェン・エムエイ・インコーポレイテッド

Absstract of: AU2012262122A1

The invention relates to methods of assessing a patient's risk of developing Progressive multifocal leukoencephalopathy (PML).